These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 18305062)

  • 21. Alemtuzumab for B-cell chronic lymphocytic leukemia.
    Hadj Tahar A
    Issues Emerg Health Technol; 2005 Mar; (66):1-4. PubMed ID: 15806747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
    Karlsson C; Hansson L; Celsing F; Lundin J
    Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
    O'Brien SM; Keating MJ; Mocarski ES
    Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
    [No Abstract]   [Full Text] [Related]  

  • 25. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
    Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
    Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
    Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
    Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
    Ferrajoli A; O'Brien SM; Cortes JE; Giles FJ; Thomas DA; Faderl S; Kurzrock R; Lerner S; Kontoyiannis DP; Keating MJ
    Cancer; 2003 Aug; 98(4):773-8. PubMed ID: 12910522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alemtuzumab in chronic lymphocytic leukemia.
    James DF; Kipps TJ
    Future Oncol; 2007 Feb; 3(1):29-42. PubMed ID: 17280499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Berlex Laboratories to market new treatment for B-CLL.
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):3. PubMed ID: 12113127
    [No Abstract]   [Full Text] [Related]  

  • 32. Alemtuzumab.
    Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
    [No Abstract]   [Full Text] [Related]  

  • 33. Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
    Laurenti L; Piccioni P; Tarnani M; Efremov DG; Fiorini A; Garzia M; Sica S
    Haematologica; 2005 Aug; 90(8):1143-5. PubMed ID: 16079121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.
    Keating MJ; Flinn I; Jain V; Binet JL; Hillmen P; Byrd J; Albitar M; Brettman L; Santabarbara P; Wacker B; Rai KR
    Blood; 2002 May; 99(10):3554-61. PubMed ID: 11986207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody therapy for chronic lymphocytic leukemia: a promising new modality.
    Lin TS; Moran M; Lucas M; Waymer S; Jefferson S; Fischer DB; Grever MR; Byrd JC
    Hematol Oncol Clin North Am; 2004 Aug; 18(4):895-913, ix-x. PubMed ID: 15325705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.
    Montillo M; Schinkoethe T; Elter T
    Cancer Invest; 2005; 23(6):488-96. PubMed ID: 16203656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
    Lee HZ; Miller BW; Kwitkowski VE; Ricci S; DelValle P; Saber H; Grillo J; Bullock J; Florian J; Mehrotra N; Ko CW; Nie L; Shapiro M; Tolnay M; Kane RC; Kaminskas E; Justice R; Farrell AT; Pazdur R
    Clin Cancer Res; 2014 Aug; 20(15):3902-7. PubMed ID: 24824310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EBV negative Richter's syndrome from a coexistent clone after salvage treatment with alemtuzumab in a CLL patient.
    Janssens A; Berth M; De Paepe P; Verhasselt B; Van Roy N; Noens L; Philippé J; Offner F
    Am J Hematol; 2006 Sep; 81(9):706-12. PubMed ID: 16838338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia.
    Kaufman MS; Caramanica A; Janson D; Driscoll N; Johnson C; Kohn N; Wasil T; Rai KR
    Med Oncol; 2011 Jun; 28(2):532-8. PubMed ID: 20237867
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.